欧根醇可以缓解5×FAD小鼠阿尔茨海默病的病理表现
Min-Ji Jung1, Namkwon Kim2, Seung Ho Jeon1
1Department of Fundamental Pharmaceutical Science, Graduate School, Kyung Hee University, Seoul, Republic of Korea.
概括
来自Syzygium aromaticum的尤根醇,在阿尔茨海默病 (AD) 的小鼠模型中改善了认知功能. 它通过抑制亡和增强微质细胞灭菌减少了粉样蛋白-β (Aβ) 斑块和神经元损失.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 阿尔茨海默病 (AD) 是一种神经退行性疾病,其特征是粉样β (Aβ) 积累,神经炎症和认知能力下降.
- 尤根醇是Syzygium aromaticum中发现的一种化合物,通过多种机制表现出神经保护和抗炎性质.
研究的目的:
- 评估eugenol在5×熟悉的AD (5×FAD) 鼠标模型中的治疗潜力.
- 研究eugenol对AD相关病理和认知功能的影响.
主要方法:
- 5×FAD和野生型小鼠接受了口服尤根醇 (10或30毫克/公斤/天) 两个月.
- 用Y迷宫和莫里斯水迷宫测试来评估认知功能.
- 进行了分子分析,以阐明eugenol的治疗机制.
主要成果:
- 在5×FAD小鼠中,Eugenol治疗显著改善了认知障碍.
- 这种改善与减少神经元细胞损失和Aβ沉积相关.
- 尤根醇抑制了亡并促进了微质细胞化,这是观察到的治疗效果的基础.
结论:
- 尤根醇显示出作为阿尔茨海默病治疗剂的潜力.
- 它减少AD关键病理的能力为治疗提供了一个有前途的途径.
相关概念视频
01:22Alzheimer's Disease: Treatment
222
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
222
01:26Alzheimer's Disease: Overview
530
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
530